Working… Menu
Trial record 25 of 36 for:    pharmacosmos

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01469078
Recruitment Status : Completed
First Posted : November 10, 2011
Last Update Posted : November 8, 2012
Information provided by (Responsible Party):
Pharmacosmos A/S

Brief Summary:
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Drug: Monofer® Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D) (PK-CKD-05)
Study Start Date : October 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 100 mg Monofer® Drug: Monofer®
Single Bolus Injections

Active Comparator: 200 mg Monofer® Drug: Monofer®
Single Bolus Injections

Active Comparator: 500 mg Monofer® Drug: Monofer®
Single Bolus Injections

Primary Outcome Measures :
  1. Determination of changes in Iron pharmacokinetic parameters from plasma/serum concentration profile [ Time Frame: From exposure to 7 days post-exposure ]
    The follwoing parameter will be determined: AUC0-t, AUC, Cmax, Tmax, Ke, and T1/2

Secondary Outcome Measures :
  1. Changes in pharmacodynamic parametres [ Time Frame: From 0 hours to 4, 8, 24, 48, 72 hours post-exposure and end of study visit ]
    Changes in the following parametres will be determined: Hemoglobin (Hb), Reticulocyte Count, Reticuloycyte Hemoglobin Content (CHr), Ferritin, Total Iron Binding Capacity (TIBC) and Transferrin Saturation (TfS)

  2. Safety evaluation [ Time Frame: From screening to 7 days post-exposure ]
    The following parameters will be evaluated: Laboratory safety variable, physical examination, vital signs and Electrocardiogram (ECG)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women, aged more than 18 years.
  2. Weight above 50 kg.
  3. Subjects diagnosed with CKD-5D and on dialysis therapy for at least 90 days prior to inclusion.
  4. Serum ferritin ≤ 800 ng/mL.
  5. Transferrin Saturation ≤ 35%.
  6. Life expectancy beyond 12 months by Principal Investigator's judgement.
  7. Hb concentrations ≥10.0 g/dL and ≤12.5 g/dL both at Screening Visit 1a and at Screening Visit 1b (Screening Visit 1a and Visit 1b must be separated by at least 1 week).
  8. Erythropoiesis Stimulating Agent (ESA) treatment (to be kept constant during the study period and for 4 weeks prior to inclusion with only one missed dose to be allowed during this pre-entry period).
  9. Subjects in maintenance iron therapy with average iron administration ≤ 100 mg/week for 4 weeks prior to inclusion and willingness to switch to investigational product.
  10. Willingness and ability to participate after informed consent (including HIPAA, if applicable).

Exclusion Criteria:

  1. Anemia caused primarily by other factors than renal related anemia.
  2. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis).
  3. Difference of Hb ≥ 1.0 g/dL between Screening Visits 1a and 1b.
  4. Known hypersensitivity to any excipients in the investigational drug products.
  5. Subjects with a history of multiple allergies.
  6. Decompensated liver cirrhosis and history of hepatitis B or C [Alanine Aminotransferase (ALT) > 3 times upper limit of normal].
  7. Acute or chronic infections (assessed by clinical investigator judgment), supported by White Blood Cells (WBC) and C-Reactive Protein (CRP).
  8. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
  9. Pregnant or nursing women.
  10. Women of child bearing potential who are not using safe contraceptive methods (e.g. intrauterine device, oral contraceptives or surgically sterilized) or who are planning to become pregnant within the study period.
  11. Blood transfusion within the previous 12 weeks.
  12. Planned elective surgery during the study where significant blood loss is expected.
  13. Participation in any other clinical trial within 3 months prior to screening.
  14. Untreated Vitamin B12 or folate deficiency.
  15. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Examples include Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.

Layout table for additonal information
Responsible Party: Pharmacosmos A/S Identifier: NCT01469078     History of Changes
Other Study ID Numbers: P-Monofer-PK-CKD-05
First Posted: November 10, 2011    Key Record Dates
Last Update Posted: November 8, 2012
Last Verified: November 2012
Keywords provided by Pharmacosmos A/S:
Chronic Kidney Disease
CKD stage 5
Iron deficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Ferric Compounds
Iron isomaltoside 1000